Categories Earnings, Health Care

Earnings preview: Advaxis stock treading near an all-time low ahead of Q2 results

Late-stage biotech firm Advaxis, Inc. (NASDAQ: ADXS) is scheduled to report second-quarter financial results on June 10, Monday, after the closing bell. Analysts expect the company to report a loss of $1.20 per share, on revenues of $0.17 million.

During the same quarter last year, the biotech firm had reported a wider loss of $4.05 per share, on higher earnings of $1.75 million.  In the past four quarters, Advaxis has twice missed earnings estimates.

pharma stocks
(Image Courtesy: Louis Reed/Unsplash)

As the company does not have any commercial products yet, it does not have any significant product revenues. The clinical trials and drug development costs are funded through various public and private offerings of its common stock, clinical collaborations, option and warrant exercises, and interest income.

The company, which focuses on discovery, development, and commercialization of immunotherapy products, has seen its stock plunge almost 90% over the past 52 weeks. The stock has declined 43% in the year-to-date period.

READ: What is NASH and which biotech companies are vying for its first-mover status

Much of this decline was contributed by the company’s decision to go ahead with a one-for-fifteen reverse stock split of its common stock in March, a move intended at maintaining stock value.

Announcement of the reverse stock split had sent the stock tumbling 20% on March 28. The move slashed the number of shares outstanding to just about 5.5 million from 82.6 million.

The stock price plunging at a rapid pace is of significant risk to the company as it represents a good amount of its financial funding.

Meanwhile, analysts are quite bullish about the stock, which has a 12-month average price target of $5.15, suggesting a 107% upside from the last close.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top